Company of the week: Resilience

Resilience plus acquired Swiftscale Biologics technology

While at Twist Bioscience, we onboarded Swiftscale Biologics technology to develop QC methods for our synthetic antibodies.

I have a great appreciation for this method of protein synthesis utilizing new "cell-free" manufacturing technologies!

Cell-free protein synthesis (cfps) is a rapid method to produce recombinant proteins in solution without involving cells.

A quote in this article from David Mace states that the CHO-cell method takes 18 months to process a DNA sequence to clinical doses for patients.
(https://lnkd.in/gBffGDX)

With this technology, the process could potentially be reduced to just a few months to process a DNA sequence to clinical doses for patients.

“Biologics production today is limited to what can be produced inside a host cell, a process that’s slow, unpredictable and hard to scale,” said Rahul Singhvi, ScD, Chief Executive Officer of Resilience
(https://lnkd.in/gudC6qRZ)

Will this promising technology have an impact on the utility of bioreactors in biotech?

Will this technology reduce time and cost of producing biopharmaceuticals drugs?

Website: https://resilience.com
They are hiring! : https://lnkd.in/g7r8B3rU

If you are interested in working Resilience, reach out to me TapBioscience so we can make sure you ace the interview and can be a great help to their team!

No cells needed.